CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. JOINT RESEARCH AND...Joint Research and Collaboration Agreement • November 9th, 2023 • Cellectis S.A. • Biological products, (no disgnostic substances) • New York
This JOINT RESEARCH AND COLLABORATION AGREEMENT (this “Agreement”) is entered into November 1, 2023 (the “Effective Date”), by and between Cellectis S.A., a Corporation under the laws of the France having a place of business at 8, rue de la Croix Jarry, 75013 Paris, France (“Cellectis”), and AstraZeneca Ireland Limited, a company incorporated in Ireland under no. 734129, whose registered office is at College Business and Technology Park, Blanchardstown, Dublin 15, D15 R925, Ireland (“AstraZeneca”). Cellectis and AstraZeneca are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. MEMORANDUM OF...Subsequent Investment Agreement • November 9th, 2023 • Cellectis S.A. • Biological products, (no disgnostic substances) • New York
CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. NOVEMBER 1, 2023...Initial Investment Agreement • November 9th, 2023 • Cellectis S.A. • Biological products, (no disgnostic substances) • New York
Words and expressions used in this agreement (the Agreement) shall be interpreted in accordance with Schedule 4 (Definitions and Interpretation).
